: The AMEDEO Literature Guide

Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Ovarian Neoplasms

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 409 articles:
HTML format
Text format

Single Articles

March 2010

JUANG CM , Yen MS, Chao KC
Reply to Dr. Markman on "Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer"
Gynecol Oncol. 2010.
PubMed Text format Related articles

DESPIERRE E , Lambrechts D, Neven P, Amant F, et al
The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DE MARZI P , Frigerio L, Cipriani S, Parazzini F, et al
Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: a clinical experience.
Gynecol Oncol. 2010;116:408-12.
PubMed Text format Related articles Abstract available

SHIH KK , Chi DS, Barakat RR, Leitao MM Jr, et al
Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 2010;116:364-9.
PubMed Text format Related articles Abstract available

GONZALEZ BOSQUET J , Terstriep SA, Cliby WA, Brown-Jones M, et al
The impact of multi-modal therapy on survival for uterine carcinosarcomas.
Gynecol Oncol. 2010;116:419-23.
PubMed Text format Related articles Abstract available

MILLER DA , Richardson S, Grigsby PW
A new method of anatomically conformal vaginal cuff HDR brachytherapy.
Gynecol Oncol. 2010;116:413-8.
PubMed Text format Related articles Abstract available

February 2010

PILS D , Wittinger M, Petz M, Gugerell A, et al
BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-ss treatment.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ANSENBERGER K , Richards C, Zhuge Y, Barua A, et al
Decreased severity of ovarian cancer and increased survival in hens fed a flaxseed-enriched diet for 1 year.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

TANNER EJ , Chi DS, Eisenhauer EL, Diaz-Montes TP, et al
Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

MARKMAN M
"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer"
Gynecol Oncol. 2010.
PubMed Text format Related articles

YIGIT R , Massuger LF, Figdor CG, Torensma R, et al
Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

HELLEMAN J , Smid M, Jansen MP, van der Burg ME, et al
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

PAUTIER P , Joly F, Kerbrat P, Bougnoux P, et al
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Gynecol Oncol. 2010;116:157-62.
PubMed Text format Related articles Abstract available

CAPO-CHICHI CD , Yeasky TM, Heiber JF, Wang Y, et al
Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
Gynecol Oncol. 2010;116:269-75.
PubMed Text format Related articles Abstract available

ROCHE MR , Rudd PJ, Krasner CN, Matulonis UA, et al
Phase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumors.
Gynecol Oncol. 2010;116:168-72.
PubMed Text format Related articles Abstract available

January 2010

MERCADO C , Zingmond D, Karlan BY, Sekaris E, et al
Quality of care in advanced ovarian cancer: The importance of provider specialty.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

BYRON SA , Gartside MG, Wellens CL, Goodfellow PJ, et al
FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DRENBERG CD , Saunders BO, Wilbanks GD, Chen R, et al
Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

ROSE SL , Kunnimalaiyaan M, Drenzek J, Seiler N, et al
Notch 1 signaling is active in ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

STEFFENSEN KD , Waldstrom M, Brandslund I, Jakobsen A, et al
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

GUARNERI V , Piacentini F, Barbieri E, Conte PF, et al
Achievements and unmet needs in the management of advanced ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

WOELBER L , Mueller V, Eulenburg C, Schwarz J, et al
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

DANGSUWAN P , Manchana T
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
Gynecol Oncol. 2010.
PubMed Text format Related articles Abstract available

RASOOL N , Fader AN, Seamon L, Neubauer NL, et al
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
Gynecol Oncol. 2010;116:10-4.
PubMed Text format Related articles Abstract available

December 2009

MARKMAN M , Moon J, Wilczynski S, Lopez AM, et al
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

RISUM S , Hogdall C, Loft A, Berthelsen AK, et al
Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MARVERTI G , Ligabue A, Guerrieri D, Paglietti G, et al
Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

WALSH CS , Blum A, Walts A, Alsabeh R, et al
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ZHAO Y , Zong ZH, Xu HM
RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ZIVANOVIC O , Sima CS, Iasonos A, Hoskins WJ, et al
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ZIGHELBOIM I , Kizer N, Taylor NP, Case AS, et al
"Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BARNETT JC , Bean SM, Whitaker RS, Kondoh E, et al
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FANFANI F , Fagotti A, Gallotta V, Ercoli A, et al
Upper abdominal surgery in advanced and recurrent ovarian cancer: Role of diaphragmatic surgery.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DIAZ JP , Tew WP, Zivanovic O, Konner J, et al
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SAED GM , Ali-Fehmi R, Jiang ZL, Fletcher NM, et al
Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DUIKER EW , van der Zee AG, de Graeff P, Boersma-van Ek W, et al
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

OSKAY-OZCELIK G , Chekerov R, Sommer H, Keil E, et al
Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: Results of a multicenter phase II study of the northeastern German society of gynecological oncology.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LESNOCK JL , Richard SD, Zorn KK, Krivak TC, et al
Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

IRMINGER-FINGER I
BARD1, a possible biomarker for breast and ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LI AJ
Application of a risk scoring system to predict surgical adverse events in the management of epithelial ovarian cancers.
Gynecol Oncol. 2009;115:323-4.
PubMed Text format Related articles

November 2009

GADDUCCI A , Cosio S, Zola P, Sostegni B, et al
The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: A multicenter retrospective Italian study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

TSOLAKIDIS D , Amant F, Van Gorp T, Leunen K, et al
Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

TAYLOR DD , Atay S, Metzinger DS, Gercel-Taylor C, et al
Characterization of humoral responses of ovarian cancer patients: Antibody subclasses and antigenic components.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ANDERSEN MR , Goff BA, Lowe KA, Scholler N, et al
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CHAN JK , Tian C, Fleming GF, Monk BJ, et al
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DIAZ JP , Abu-Rustum NR, Sonoda Y, Downey RJ, et al
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CHAN JK , Tian C, Teoh D, Monk BJ, et al
Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

O'CEARBHAILL R , Zhou Q, Iasonos A, Hensley ML, et al
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LANDRISCINA M , Amoroso MR, Piscazzi A, Esposito F, et al
Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

KHALIL I , Brewer MA, Neyarapally T, Runowicz CD, et al
The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

NAM EJ , Yun MJ, Oh YT, Kim JW, et al
Diagnosis and staging of primary ovarian cancer: Correlation between PET/CT, Doppler US, and CT or MRI.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

GRAY HJ , Shah CA, Swensen RE, Tamimi HK, et al
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ROCERETO TF , Brady WE, Shahin MS, Hoffman JS, et al
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DUSKA LR , Garrett L, Henretta M, Ferriss JS, et al
When 'never-events' occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

O'DONNELL JD , Linger RJ, Kruk PA
BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

WINER I , Buckanovich RJ
A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.
Gynecol Oncol. 2009.
PubMed Text format Related articles

JOLY F , Sevin E, Lortholary A, Priou F, et al
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

NELSON BH
IDO and outcomes in ovarian cancer.
Gynecol Oncol. 2009;115:179-80.
PubMed Text format Related articles

October 2009

RECCHIA F , Di Orio F, Candeloro G, Guerriero G, et al
Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MOORE RG , Maclaughlan S, Bast RC Jr
Current state of biomarker development for clinical application in epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DIETRICH CS 3RD , Greenberg VL, Desimone CP, Modesitt SC, et al
Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BENDORAITE A , Knouf EC, Garg KS, Parkin RK, et al
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MATEI DE , Nephew KP
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SCOLES DR , Xu X, Wang H, Tran H, et al
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FAGOTTI A , Fanfani F, Vizzielli G, Gallotta V, et al
Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SABBATINI P , Spriggs D, Aghajanian C, Hensley M, et al
Consolidation strategies in ovarian cancer: Observations for future clinical trials.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

EINENKEL J , Wuttke P, Horn K
Should the extreme drug resistance assay fade into oblivion? Commentary on Karam, A.K., Chiang, J.W., Fung, E., Nossov, V. and Karlan, B.Y. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol O
Gynecol Oncol. 2009.
PubMed Text format Related articles

KARAM AK , Karlan BY
Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles

KANG WD , Choi HS, Kim SM
Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CADRON I , Van Gorp T, Timmerman D, Amant F, et al
Application of proteomics in ovarian cancer: Which sample should be used?
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

HURT JD , Richardson DL, Seamon LG, Fowler JF, et al
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

VERNOOIJ F , Witteveen PO, Verweij E, van der Graaf Y, et al
The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ALVAREZ RD , Mannel R, Garcia AA, Gallion HH, et al
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: Results of a three-arm Phase I study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

AGGARWAL S , He T, Fitzhugh W, Rosenthal K, et al
Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

September 2009

YANAZUME S , Eto T, Saito T, Okadome M, et al
Diaphragmatic defect complicated with massive pleural effusion in a patient with bulky ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles

HOEKSTRA AV , Hurteau JA, Kirschner CV, Rodriguez GC, et al
The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

JANDIAL DD , Messer K, Farshchi-Heydari S, Pu M, et al
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

JOLY F , Petit T, Pautier P, Guardiola E, et al
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

HOLLOWAY RW
Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles

JEWELL EL , Darcy KM, Hutson A, Lee PS, et al
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BRISTOW RE , Zahurak ML, Diaz-Montes TP, Giuntoli RL, et al
Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

WANG FQ , Barfield E, Dutta S, Pua T, et al
VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ZIVANOVIC O , Carter J, Kauff ND, Barakat RR, et al
A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer, with the presentation of two cases.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BOIVIN M , Lane D, Piche A, Rancourt C, et al
CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LIOTTA M , Rose PG, Escobar PF
Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles

LEITAO MM JR , Natenzon A, Abu-Rustum NR, Chi DS, et al
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

August 2009

FOSTER T , Brown TM, Chang J, Menssen HD, et al
A review of the current evidence for maintenance therapy in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

AGHAJANIAN C , Blessing JA, Darcy KM, Reid G, et al
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BEAUCHAMP MC , Knafo A, Yasmeen A, Carboni JM, et al
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BRISTOW RE , Chi DS
Response to "Indefinitely prolonged survival after relapse in advanced ovarian cancer: The other end of the telescope"
Gynecol Oncol. 2009.
PubMed Text format Related articles

MARKMAN M
Comparative effectiveness research: A proposal for funding in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles

KUMPULAINEN S , Sankila R, Leminen A, Kuoppala T, et al
The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - A prospective nation-wide study in Finland.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

INABA T , Ino K, Kajiyama H, Yamamoto E, et al
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ZIVANOVIC O , Sima CS, Iasonos A, Bell-McGuinn KM, et al
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BOYCE EA , Costaggini I, Vitonis A, Feltmate C, et al
The epidemiology of ovarian granulosa cell tumors: A case-control study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

PRISTAUZ G , Bader AA, Regitnig P, Haas J, et al
How accurate is frozen section histology of pelvic lymph nodes in patients with endometrial cancer?
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SONG YJ , Lim MC, Kang S, Seo SS, et al
Total colectomy as part of primary cytoreductive surgery in advanced Mullerian cancer.
Gynecol Oncol. 2009;114:183-7.
PubMed Text format Related articles Abstract available

ZIVANOVIC O , Aldini A, Carlson JW, Chi DS, et al
Advanced cytoreductive surgery: American perspective.
Gynecol Oncol. 2009;114.
PubMed Text format Related articles Abstract available

CRANDON AJ , Obermair A
Advanced cytoreductive surgery: Asia Pacific perspective.
Gynecol Oncol. 2009;114.
PubMed Text format Related articles Abstract available

VERLEYE L , Ottevanger PB, Vergote I
Surgical program building in advanced ovarian cancer: European perspective.
Gynecol Oncol. 2009;114.
PubMed Text format Related articles Abstract available

BRISTOW RE
Advanced cytoreductive surgery in gynecologic oncology.
Gynecol Oncol. 2009;114.
PubMed Text format Related articles

July 2009

TAYLOR DD , Gercel-Taylor C, Parker LP
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MARKMAN M
Response to: "Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomastis (Chua TC, et al.)"
Gynecol Oncol. 2009.
PubMed Text format Related articles

WETHINGTON SL , Barrena Medel NI, Wright JD, Herzog TJ, et al
Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

POWLESS CA , Bakkum-Gamez JN, Aletti GD, Cliby WA, et al
Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

NOSKOVA V , Ahmadi S, Asander E, Casslen B, et al
Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CHI DS , Bristow RE
In response to: Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis.
Gynecol Oncol. 2009.
PubMed Text format Related articles

FOLKINS AK , Saleemuddin A, Garrett LA, Garber JE, et al
Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CHUA TC , Liauw W, Robertson G, Morris DL, et al
Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis.
Gynecol Oncol. 2009.
PubMed Text format Related articles

KRIVAK TC , Tian C, Rose GS, Armstrong DK, et al
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MATEI D , Schilder J, Sutton G, Perkins S, et al
Activity of 2 methoxyestradiol (Panzem((R)) NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

VICUS D , Rosen B, Lubinski J, Domchek S, et al
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

YEN MS , Twu NF, Lai CR, Horng HC, et al
Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SCHLOSSHAUER PW , Li W, Lin KT, Chan JL, et al
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BERCHUCK A
Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
Gynecol Oncol. 2009;114:1-2.
PubMed Text format Related articles

MAGGIONI A , Roviglione G, Landoni F, Zanagnolo V, et al
Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.
Gynecol Oncol. 2009;114:64-8.
PubMed Text format Related articles Abstract available

ALETTI GD , Powless C, Bakkum-Gamez J, Wilson TO, et al
Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy.
Gynecol Oncol. 2009;114:32-6.
PubMed Text format Related articles Abstract available

CHANG HL , Pahlavan N, Halpern EF, MacLaughlin DT, et al
Serum Mullerian Inhibiting Substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.
Gynecol Oncol. 2009;114:57-60.
PubMed Text format Related articles Abstract available

June 2009

ARIAS-PULIDO H , Smith HO, Joste NE, Bocklage T, et al
Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BRYANT CS , Kumar S, Shah JP, Mahdi H, et al
Racial disparities in survival among patients with germ cell tumors of the ovary-United States.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

IVY JJ , Geller M, Pierson SM, Jonson AL, et al
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: A single institution's experience.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SILVER DF , Zgheib NB
Extended left colon resections as part of complete cytoreduction for ovarian cancer: Tips and considerations.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SFAKIANOS GP , Numnum TM, Halverson CB, Panjeti D, et al
The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FULHAM MJ , Carter J, Hicks R
The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project: Response to a letter from Dr. Maure Markman.
Gynecol Oncol. 2009.
PubMed Text format Related articles

TAO X , Sood AK, Deavers MT, Schmeler KM, et al
Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

DARCY KM , Brady WE, Blancato JK, Dickson RB, et al
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

POWER P , Stuart G, Oza A, Provencher D, et al
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BACKES FJ , Leon ME, Ivanov I, Suarez A, et al
Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

KAPNICK J , Helgason H
Indefinitely prolonged survival after relapse in advanced ovarian cancer: The other end of the telescope.
Gynecol Oncol. 2009.
PubMed Text format Related articles

SMITH HO , Arias-Pulido H, Kuo DY, Howard T, et al
GPR30 predicts poor survival for ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

HU X , Macdonald DM, Huettner PC, Feng Z, et al
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FOLKINS AK , Jarboe EA, Roh MH, Crum CP, et al
Precursors to pelvic serous carcinoma and their clinical implications.
Gynecol Oncol. 2009;113:391-6.
PubMed Text format Related articles Abstract available

May 2009

BRISTOW RE , Peiretti M, Gerardi M, Zanagnolo V, et al
Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: Operative technique and clinical outcome.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MARKMAN M
The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.
Gynecol Oncol. 2009.
PubMed Text format Related articles

HARIRI LP , Bonnema GT, Schmidt K, Winkler AM, et al
Laparoscopic optical coherence tomography imaging of human ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

WU TI , Lee CL, Wu MY, Hsueh S, et al
Prognostic factors predicting recurrence in borderline ovarian tumors.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MIRABEAU-BEALE KL , Kornblith AB, Penson RT, Lee H, et al
Comparison of the quality of life of early and advanced stage ovarian cancer survivors.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FADER AN , Escobar PF
Laparoendoscopic single-site surgery (LESS) in gynecologic oncology: Technique and initial report.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SMITH HO , Moon J, Wilczynski SP, Tiersten AD, et al
Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LURIE G , Thompson PJ, McDuffie KE, Carney ME, et al
Prediagnostic symptoms of ovarian carcinoma: A case-control study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FOTIOU S , Aliki T, Petros Z, Ioanna S, et al
Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

WANG L , Madigan MC, Chen H, Liu F, et al
Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ROCCONI RP , Matthews KS, Kemper MK, Hoskins KE, et al
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MARKMAN M , Liu PY, Moon J, Monk BJ, et al
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m(2)) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic On
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

TANYI JL , Smith JA, Ramos L, Parker CL, et al
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

KANG H , Kim TJ, Lee YY, Choi CH, et al
Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

EITAN R , Kushnir M, Lithwick-Yanai G, David MB, et al
Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MEIER W , du Bois A, Reuss A, Kuhn W, et al
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolo
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SAFRA T , Menczer J, Bernstein RM, Shpigel S, et al
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FARGHALY SA
Observation on the surgical aspect of resection of noncolorectal nonneuroendocrine hepatic parenchymal metastasis in patients with primary epithelial ovarian carcinoma.
Gynecol Oncol. 2009.
PubMed Text format Related articles

LOWE KA , Andersen MR, Urban N, Paley P, et al
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

PEEDICAYIL A , Vierkant RA, Shridhar V, Schildkraut JM, et al
Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

TAN W , Stehman FB, Carter RL
Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

April 2009

CHIEN J , Fan JB, Bell DA, April C, et al
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

NAUMANN RW , Sukumvanich P, Edwards RP
Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BOSE CK
Is randomized trial of neoadjuvant chemotherapy of ovarian cancer necessary?
Gynecol Oncol. 2009.
PubMed Text format Related articles

MARKMAN M
In response to: "Towards randomized trials of peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis"
Gynecol Oncol. 2009.
PubMed Text format Related articles

TSAI-TURTON M , Santillan A, Lu D, Bristow RE, et al
p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LAN C , Li Y, Liu J
Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

GHAMANDE SA , Silverman M, Gold M
A Phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles

CHI DS , Eisenhauer EL, Zivanovic O, Sonoda Y, et al
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FERGUSON SE , Malhotra T, Seshan VE, Levine DA, et al
A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CAI KQ , Wu H, Klein-Szanto AJ, Xu XX, et al
Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CHUA TC , Liauw W, Robertson G, Chia WK, et al
Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis.
Gynecol Oncol. 2009.
PubMed Text format Related articles

GERSHENSON DM , Sun CC, Bodurka D, Coleman RL, et al
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FENNIMORE IA , Simon NL, Bills G, Dryfhout VL, et al
Extension of ovarian tissue into the infundibulopelvic ligament beyond visual margins.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FAGOTTI A , Paris I, Grimolizzi F, Fanfani F, et al
Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

TIRO AV , Talukdar R, Lewis MG
A unique case of serous psammocarcinoma of the ovary presenting with pleural effusion and manifesting psammoma body implants in the pleural cavity and pericardium.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

OREZZOLI JP , Sioletic S, Olawaiye A, Oliva E, et al
Stage II endometrioid adenocarcinoma of the endometrium: Clinical implications of cervical stromal invasion.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

Hereditary breast and ovarian cancer syndrome.
Gynecol Oncol. 2009;113:6-11.
PubMed Text format Related articles

GERESTEIN CG , Damhuis RA, Burger CW, Kooi GS, et al
Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: A systematic review.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

March 2009

ANSENBERGER K , Zhuge Y, Lagman JA, Richards C, et al
E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

GUPTA D , Owers RL, Kim M, Kuo DY, et al
A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

KARAM AK , Chiang JW, Fung E, Nossov V, et al
Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SHIMADA M , Kigawa J, Ohishi Y, Yasuda M, et al
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FARLEY J , Fuchiuji S, Darcy KM, Tian C, et al
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SCHMELER KM , Vadhan-Raj S, Ramirez PT, Apte SM, et al
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BEGUM FD , Hogdall E, Kjaer SK, Blaakaer J, et al
Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

WALKER JL
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.
Gynecol Oncol. 2009;112:439-40.
PubMed Text format Related articles

ENGLE DB , Belisle JA, Gubbels JA, Petrie SE, et al
Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Gynecol Oncol. 2009;112:631-6.
PubMed Text format Related articles Abstract available

February 2009

KEHOE SM , Williams NL, Yakubu R, Levine DA, et al
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LEFFERS N , Gooden MJ, Mokhova AA, Kast WM, et al
Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

ARGENTA PA , Thomas SG, Judson PL, Downs LS Jr, et al
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BOREN T , Xiong Y, Hakam A, Wenham R, et al
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FREDERICK PJ , Straughn JM Jr, Alvarez RD, Buchsbaum DJ, et al
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

HAVRILESKY LJ , Broadwater G, Davis DM, Nolte KC, et al
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

TAKAHASHI A , Kato K, Kuboyama A, Inoue T, et al
Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

KIM HS , Kim MK, Chung HH, Kim JW, et al
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BERRY E , Matthews KS, Singh DK, Buttin BM, et al
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

KLASA-MAZURKIEWICZ D , Narkiewicz J, Milczek T, Lipinska B, et al
Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MATULONIS UA , Krag KJ, Krasner CN, Atkinson T, et al
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors.
Gynecol Oncol. 2009;112:394-9.
PubMed Text format Related articles Abstract available

January 2009

ONDA T , Kobayashi H, Nakanishi T, Hatae M, et al
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MICHELSEN TM , Dorum A, Dahl AA
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

YANG XY , Xi MR, Yang KX, Yu H, et al
Prognostic value of estrogen receptor and progesterone receptor status in Chinese young ovarian carcinoma patients.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MARKMAN M
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation.
Gynecol Oncol. 2009.
PubMed Text format Related articles

GREVING JP , Vernooij F, Heintz AP, van der Graaf Y, et al
Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

PARK JY , Kim DY, Kim JH, Kim YM, et al
Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

QUINN JE , Carser JE, James CR, Kennedy RD, et al
BRCA1 and implications for response to chemotherapy in ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BROWN J , Sood AK, Deavers MT, Milojevic L, et al
Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SCHILDER RJ , Pathak HB, Lokshin AE, Holloway RW, et al
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

HOYER PB , Davis JR, Bedrnicek JB, Marion SL, et al
Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FULHAM MJ , Carter J, Baldey A, Hicks RJ, et al
The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

HEUBNER M , Riemann K, Otterbach F, Kimmig R, et al
The haplotype of two FSHR polymorphisms in ovarian cancer- A potential role of ethnology in risk modification.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MCLEAN K , Vandeven NA, Sorenson DR, Daudi S, et al
The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

LEE YK , Park NH
Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

FANG CY , Cherry C, Devarajan K, Li T, et al
A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

MARKMAN M
"A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer"
Gynecol Oncol. 2009.
PubMed Text format Related articles

TIERSTEN AD , Liu PY, Smith HO, Wilczynski SP, et al
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

VERNOOIJ F , Heintz AP, Coebergh JW, Massuger LF, et al
Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in The Netherlands.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

RUBATT JM , Darcy KM, Hutson A, Bean SM, et al
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SHIELD K , Ackland ML, Ahmed N, Rice GE, et al
Multicellular spheroids in ovarian cancer metastases: Biology and pathology.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

CHIN SN , Pinto V, Rosen B, Oza A, et al
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

SHETH RA , Upadhyay R, Stangenberg L, Sheth R, et al
Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model.
Gynecol Oncol. 2009.
PubMed Text format Related articles Abstract available

BRISTOW RE
Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen.
Gynecol Oncol. 2009;112:1-3.
PubMed Text format Related articles

VORGIAS G , Iavazzo C, Savvopoulos P, Myriokefalitaki E, et al
Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.
Gynecol Oncol. 2009;112:11-5.
PubMed Text format Related articles Abstract available

CHI DS , Zivanovic O, Palayekar MJ, Eisenhauer EL, et al
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
Gynecol Oncol. 2009;112:6-10.
PubMed Text format Related articles Abstract available

December 2008

WILLIAMS SJ , Cvetkovic D, Hamilton TC
Vitamin A metabolism is impaired in human ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

JONGEN V , Briet J, de Jong R, Ten Hoor K, et al
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

CAMUZCUOGLU H , Arioz DT, Toy H, Kurt S, et al
Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

KARAM AK , Stempel M, Barakat RR, Morrow M, et al
Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

KEHOE SM , Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al
Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ATMACA A , Al-Batran SE, Neumann A, Kolassa Y, et al
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - A phase II study.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

MATTHEWS KS , Straughn JM Jr, Kemper MK, Hoskins KE, et al
The effect of obesity on survival in patients with ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

FUJIMOTO T , Nanjyo H, Fukuda J, Nakamura A, et al
Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

CHI DS , Schwartz PE
Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer.
Gynecol Oncol. 2008;111:391-9.
PubMed Text format Related articles

GILANI MM , Karimi Zarchi M, Ghaemmaghami F, Behtash N, et al
Retraction notice to "A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer" [Gynecol. Oncol. 105 (2007) 780-783].
Gynecol Oncol. 2008;111:516.
PubMed Text format Related articles

SCHONMAN R , Klein Z, Edelstein E, Czernobilsky B, et al
Luteinized thecoma associated with sclerosing peritonitis--conservative surgical approach followed by corticosteroid and GnRH agonist treatment--a case report.
Gynecol Oncol. 2008;111:540-3.
PubMed Text format Related articles Abstract available

BRYANT CS , Shah JP, Triest JA, Schimp VL, et al
Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus.
Gynecol Oncol. 2008;111:552-4.
PubMed Text format Related articles Abstract available

YANG GF , Xie D, Liu JH, Luo JH, et al
Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

November 2008

LANDRUM LM , Moore KN, Myers TK, Lanneau GS Jr, et al
Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ALETTI GD , Podratz KC, Moriarty JP, Cliby WA, et al
Aggressive and complex surgery for advanced ovarian cancer: An economic analysis.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

METCALFE KA , Fan I, McLaughlin J, Risch HA, et al
Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

CHEN LL , Ye F, Yu Y, Chen HZ, et al
Ovarian carcinoma cells influence differentiation of Lin-CD45RA- dendritic cell precursors into two mature subtypes in vitro.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

TANGJITGAMOL S , Manusirivithaya S, Laopaiboon M, Lumbiganon P, et al
Interval debulking surgery for advanced epithelial ovarian cancer: A Cochrane systematic review.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

LIM MC , Kang S, Lee KS, Han SS, et al
The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ANDERSON NS , Bermudez Y, Badgwell D, Chen R, et al
Urinary levels of Bcl-2 are elevated in ovarian cancer patients.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

WATARI H , Xiong Y, Hassan MK, Sakuragi N, et al
Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

NOLEN B , Marrangoni A, Velikokhatnaya L, Prosser D, et al
A serum based analysis of ovarian epithelial tumorigenesis.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

HO CM , Lin MC, Huang SH, Huang CJ, et al
PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

INGERSOLL SB , Patel S, Caballero L, Ahmad S, et al
Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

DU BOIS A , Rochon J, Pfisterer J, Hoskins WJ, et al
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

URICK ME , Giles JR, Johnson PA
Dietary aspirin decreases the stage of ovarian cancer in the hen.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

MORICE P , Uzan C, Gouy S, Pautier P, et al
Results of conservative treatment of epithelial ovarian tumor.
Gynecol Oncol. 2008.
PubMed Text format Related articles

ROBINSON W , Ritter J, Rogers A, Tedjarati S, et al
Participation in clinical research is associated with improved survival in women with ovarian cancer.
Gynecol Oncol. 2008;111:386.
PubMed Text format Related articles

RAJ M , Abd Elmageed Z, Zhou J, Gaur RL, et al
Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells.
Gynecol Oncol. 2008;111:385.
PubMed Text format Related articles

YU X , Cohen J, Deshmukh H, Zhang R, et al
The association of serial ultrasounds and CA125 prior to diagnosis of ovarian cancer-Do they improve early detection?
Gynecol Oncol. 2008;111:385-6.
PubMed Text format Related articles

CONNOR J , Felder M
Ascites from epithelial ovarian cancer contains high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance and poor patient outcome.
Gynecol Oncol. 2008;111:384-5.
PubMed Text format Related articles

URBAN R , Deshmukh H, Zhang R, Yu X, et al
The impact of chemotherapy on the survival of early-stage I-II epithelial ovarian cancer.
Gynecol Oncol. 2008;111:382.
PubMed Text format Related articles

ELFRINK SH , Myers TK, Gold MA, Walker JL, et al
Chemotherapy in recurrent ovarian cancer: What clinical benefit should be expected?
Gynecol Oncol. 2008;111:380.
PubMed Text format Related articles

PAPADIA A , Schally AV, Seitz S, Buchholz S, et al
Experimental therapy of ES-2 human platinum resistant ovarian cancer with targeted cytotoxic somatostatin and LHRH analogues.
Gynecol Oncol. 2008;111:376.
PubMed Text format Related articles

MCLEAN KA , Shah CA, Thompson SA, Gray HJ, et al
Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction.
Gynecol Oncol. 2008;111:375-6.
PubMed Text format Related articles

BREWSTER WR
The complexity of race in the disparate outcome and treatment of minority patients.
Gynecol Oncol. 2008;111:161-2.
PubMed Text format Related articles

KEHOE SM , Eisenhauer EL, Chi DS
Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy.
Gynecol Oncol. 2008;111.
PubMed Text format Related articles Abstract available

SALEEMUDDIN A , Folkins AK, Garrett L, Garber J, et al
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.
Gynecol Oncol. 2008;111:226-32.
PubMed Text format Related articles Abstract available

October 2008

MUGGIA F
Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

HSIAO SM , Chen CA, Lin HH, Hsieh CY, et al
Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox(R)) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ADLEY BP , Gleason KJ, Yang XJ, Stack MS, et al
Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: High level expression in clear cell carcinoma.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ZHUGE Y , Lagman JA, Ansenberger K, Mahon CJ, et al
CYP1B1 expression in ovarian cancer in the laying hen Gallusdomesticus.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

FAN T , Zhao Q, Chen JJ, Chen WT, et al
Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

RESNICK KE , Alder H, Hagan JP, Richardson DL, et al
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

CHURA JC , Blomquist CH, Ryu HS, Argenta PA, et al
Estrone sulfatase activity in patients with advanced ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ALETTI GD , Podratz KC, Cliby WA, Gostout BS, et al
Stage IV ovarian cancer: Disease site-specific rationale for postoperative treatment.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ZIOLKOWSKA-SETA I , Madry R, Kraszewska E, Szymanska T, et al
TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

BRISTOW RE , Puri I, Chi DS
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

NEVADUNSKY NS , Barbieri JS, Kwong J, Merritt MA, et al
RUNX3 protein is overexpressed in human epithelial ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

SCHWAB KV , O'Malley DM, Fowler JM, Copeland LJ, et al
Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

MAZGANI M , Le N, Hoskins PJ
Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer-the British Columbia Cancer Agency experience.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

COOSEMANS A , Moerman P, Verbist G, Maes W, et al
Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

FAGOTTI A , Francesco F, Giovanni S
Re: "External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score"
Gynecol Oncol. 2008.
PubMed Text format Related articles

MOORE RG , McMeekin DS, Brown AK, Disilvestro P, et al
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

HOFFMAN MS , Zervose E
Colon resection for ovarian cancer: Intraoperative decisions.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

September 2008

ARANDA MA , McGory M, Sekeris E, Maggard M, et al
Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer?
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

DARCY KM , Brady WE, McBroom JW, Bell JG, et al
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

HERZOG TJ , Powell MA, Rader JS, Gibb RK, et al
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

RICHARDSON DL , Backes FJ, Seamon LG, Zanagnolo V, et al
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

SABBATINI P , Sill MW, O'Malley D, Adler L, et al
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

SORRENTINO A , Liu CG, Addario A, Peschle C, et al
Role of microRNAs in drug-resistant ovarian cancer cells.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

TERPLAN M , Temkin S, Tergas A, Lengyel E, et al
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

HASHIMOTO H , Sudo T, Mikami Y, Otani M, et al
Germ cell specific protein VASA is over-expressed in epithelial ovarian cancer and disrupts DNA damage-induced G2 checkpoint.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

TAKAI N , Ueda T, Nasu K, Narahara H, et al
Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

TANNER EJ , Zahurak ML, Bristow RE, Diaz-Montes TP, et al
Surgical care of young women diagnosed with ovarian cancer: A population-based perspective.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

RICHARDSON DL , Seamon LG, Carlson MJ, O'Malley DM, et al
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

August 2008

FENG Q , Deftereos G, Hawes SE, Stern JE, et al
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

GHAMANDE SA , Silverman MH, Huh W, Behbakht K, et al
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

CONNOR JP , Felder M
Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

HAVRILESKY LJ , Sanders GD, Kulasingam S, Myers ER, et al
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

FERRANDINA G , Martinelli E, Petrillo M, Prisco MG, et al
Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

KESTERSON JP , Mhawech-Fauceglia P, Lele S
The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

ROCCONI RP
Re: Chemotherapy-related myelosuppression as a marker for survival in epithelial ovarian cancer patients.
Gynecol Oncol. 2008.
PubMed Text format Related articles

WANG J , Zhang X, Ge X, Guo H, et al
Proteomic studies of early-stage and advanced ovarian cancer patients.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

KIMBALL KJ , Numnum TM, Kirby TO, Zamboni WC, et al
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

LACOUR RA , Daniels MS, Westin SN, Meyer LA, et al
What women with ovarian cancer think and know about genetic testing.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

WOO MM , Salamanca CM, Symowicz J, Stack MS, et al
SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

GERSHENSON DM
SEER data: perspective at 10,000 feet.
Gynecol Oncol. 2008;110:121-2.
PubMed Text format Related articles

July 2008

KANG H , Kim TJ, Kim WY, Choi CH, et al
Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

PETRU E
Re: Chemotherapy-related myelosuppression as a marker for survival in epithelial ovarian cancer patients by Rocconi et al.
Gynecol Oncol. 2008.
PubMed Text format Related articles

CROOG VJ , Abu-Rustum NR, Barakat RR, Alektiar KM, et al
Adjuvant radiation for early stage endometrial cancer with lymphovascular invasion.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

OREZZOLI JP , Russell AH, Oliva E, Del Carmen MG, et al
Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
Gynecol Oncol. 2008.
PubMed Text format Related articles Abstract available

MCALPINE JN , Eisenkop SM, Spirtos NM
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

QAMAR L , Davis R, Anwar A, Behbakht K, et al
Protein kinase C inhibitor Go6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

URICK ME , Giles JR, Johnson PA
VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

RAJ MH , Abd Elmageed ZY, Zhou J, Gaur R, et al
Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

AUERSPERG N , Woo MM, Gilks CB
The origin of ovarian carcinomas: A developmental view.
Gynecol Oncol. 2008;.
PubMed Text format Related articles

TAYLOR DD , Gercel-Taylor C
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
Gynecol Oncol. 2008;110:13-21.
PubMed Text format Related articles Abstract available

SHIH KK , Levine DA
Exosomal microRNAs step into the biomarker arena.
Gynecol Oncol. 2008;110:1-2.
PubMed Text format Related articles

TSILI AC , Tsampoulas C, Charisiadi A, Kalef-Ezra J, et al
Adnexal masses: accuracy of detection and differentiation with multidetector computed tomography.
Gynecol Oncol. 2008;110:22-31.
PubMed Text format Related articles Abstract available

June 2008

SALVADOR S , Rempel A, Soslow RA, Gilks B, et al
Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MORGAN MA , Darcy KM, Rose PG, Degeest K, et al
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncology Group.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

JOHNSON CC , Kessel B, Riley TL, Ragard LR, et al
The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MARKMAN M
Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: A strategy to improve the quality of gynecologic cancer clinical research.
Gynecol Oncol. 2008;.
PubMed Text format Related articles

PARK JY , Kim DY, Suh DS, Kim JH, et al
Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: Oncologic safety and reproductive outcomes.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

HAVRILESKY LJ , Whitehead CM, Rubatt JM, Cheek RL, et al
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BRUN JL , Rouzier R, Uzan S, Darai E, et al
External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

LEFFERS N , Lambeck AJ, de Graeff P, Bijlsma AY, et al
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

KUMAR S , Shah JP, Bryant CS, Imudia AN, et al
The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

HAMILTON CA , Maxwell GL, Chernofsky MR, Bernstein SA, et al
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

KONNER J , Schilder RJ, Derosa FA, Gerst SR, et al
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

CHAN KK , Tam KF, Tse KY, Ngan HY, et al
The role of regular physical examination in the detection of ovarian cancer recurrence.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

COHN DE , Hall NC, Povoski SP, Seamon LG, et al
Novel perioperative imaging with (18)F-FDG PET/CT and intraoperative (18)F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

QU D , Qu H, Fu M, Zhao X, et al
Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

GOFF BA , Holmberg LA, Veljovich D, Kurland BF, et al
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan A phase II trial of the Puget Sound Oncology Consortium.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

KAJIYAMA H , Shibata K, Suzuki S, Ino K, et al
Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

DORUM A , Tonstad S, Liavaag AH, Michelsen TM, et al
Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2).
Gynecol Oncol. 2008;109:377-83.
PubMed Text format Related articles Abstract available

May 2008

DEVINE KM , Smicun Y, Hope JM, Fishman DA, et al
S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

GOTLIEB WH , Saumet J, Beauchamp MC, Gu J, et al
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MURDOCH WJ , Van Kirk EA, Isaak DD, Shen Y, et al
Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MOORE KN , Reid MS, Fong DN, Myers TK, et al
Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

REN J , Peng Z, Yang K
A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

RAMIREZ PT , Schmeler KM, Milam MR, Slomovitz BM, et al
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BOYD J
Whence epithelial ovarian carcinoma?
Gynecol Oncol. 2008;109:161-3.
PubMed Text format Related articles

RIEDINGER JM , Eche N, Basuyau JP, Dalifard I, et al
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Gynecol Oncol. 2008;109:194-8.
PubMed Text format Related articles Abstract available

April 2008

QUIROS RM , Valianou M, Kwon Y, Brown KM, et al
Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

DURRANT D , Richards JE, Walker WT, Baker KA, et al
Mechanism of cell death induced by cis-3, 4', 5-trimethoxy-3'-aminostilbene in ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BAEK WS , Kubba SV
Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

WENZEL L , Huang HQ, Cella D, Walker JL, et al
Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: A Gynecologic Oncology Group study.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

NIMEIRI HS , Oza AM, Morgan RJ, Friberg G, et al
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BULL PHELPS SL , Schorge JO, Peyton MJ, Shigematsu H, et al
Implications of EGFR inhibition in ovarian cancer cell proliferation.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MORRIS R , Alvarez RD, Andrews S, Malone J, et al
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

WRIGHT JD , Tian C, Mutch DG, Herzog TJ, et al
Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

LEE HP , Seo SS, Ryu SY, Kim JH, et al
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

HARLEY I , Rosen B, Risch HA, Siminovitch K, et al
Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BRISTOW RE , Peiretti M, Zanagnolo V, Salani R, et al
Transverse colectomy in ovarian cancer surgical cytoreduction: Operative technique and clinical outcome.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

CHAN JK , Teoh D, Hu JM, Shin JY, et al
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

PUCA R , Nardinocchi L, Pistritto G, D'Orazi G, et al
Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

March 2008

DOWDY SC , Loewen RT, Aletti G, Feitoza SS, et al
Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BOUCHARDY C , Fernandez S, Merglen A, Usel M, et al
Increased risk of second cancer among patients with ovarian borderline tumors.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

LI AJ , Scoles DR, Armstrong KU, Karlan BY, et al
Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

FERRANDINA G , Ludovisi M, Corrado G, Carone V, et al
Prognostic role of ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

LITKOUHI B , Litkouhi B, Fleming E, Welch WR, et al
Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

SINGH RK , Lange TS, Kim KK, Shaw SK, et al
A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

CHOI M , Fuller CD, Thomas CR Jr, Wang SJ, et al
Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

SENGUPTA S , Michener CM, Escobar P, Belinson J, et al
Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

WOODS DC , Alvarez C, Johnson AL
Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
Gynecol Oncol. 2008;108:632-40.
PubMed Text format Related articles Abstract available

February 2008

SHAH CA , Allison KH, Garcia RL, Gray HJ, et al
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

ALBERTS DS , Marth C, Alvarez RD, Johnson G, et al
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of pro
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

KONECNY GE , Agarwal R, Keeney GA, Winterhoff B, et al
Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

OEI AL , Sweep FC, Massuger LF, Olthaar AJ, et al
Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MODESITT SC , Sill M, Hoffman JS, Bender DP, et al
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

SOEDA S , Nakamura N, Ozeki T, Nishiyama H, et al
Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

STAMMER K , Edassery SL, Barua A, Bitterman P, et al
Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

LINCH M , Stavridi F, Hook J, Barbachano Y, et al
Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

FADER AN , Gruenigen VV, Gibbons H, Abushahin F, et al
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

AYHAN A , Gultekin M, Dursun P, Dogan NU, et al
Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?
Gynecol Oncol. 2008;108:428-32.
PubMed Text format Related articles Abstract available

GIL OD , Lee C, Ariztia EV, Wang FQ, et al
Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.
Gynecol Oncol. 2008;108:361-9.
PubMed Text format Related articles Abstract available

January 2008

TAYLOR SA , Marrinan CH, Liu G, Nale L, et al
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BARTON CA , Hacker NF, Clark SJ, O'Brien PM, et al
DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MARKMAN M
Evidence-based chemotherapy administration in advanced ovarian cancer: An impressive past, a disquieting present and an uncertain future.
Gynecol Oncol. 2008;.
PubMed Text format Related articles

BLACK D , Levine DA, Nicoll L, Chou JF, et al
Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

TAKAI N , Ueda T, Nishida M, Nasu K, et al
beta-Hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

KALLI KR , Oberg AL, Keeney GL, Christianson TJ, et al
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

ZHOU B , Sun Q, Cong R, Gu H, et al
Hormone replacement therapy and ovarian cancer risk: A meta-analysis.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

MARKMAN M
Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials.
Gynecol Oncol. 2008;.
PubMed Text format Related articles

SABBATINI P , Harrison ML
Response to Dr. Markman regarding "Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials.
Gynecol Oncol. 2008;.
PubMed Text format Related articles

PARK JY , Kim EN, Kim DY, Suh DS, et al
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

SECORD AA , Blessing JA, Armstrong DK, Rodgers WH, et al
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

HOCHSTER H , Chen TT, Lu JM, Hills D, et al
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

BUTTIN BM , Moore MJ
Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

LEE YK , Park NH, Kim JW, Song YS, et al
Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

OZBUDAK IH , Karaveli S, Simsek T, Erdogan G, et al
Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

CACERES A , Zhou Q, Iasonos A, Gerdes H, et al
Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: An updated series.
Gynecol Oncol. 2008;.
PubMed Text format Related articles Abstract available

December 2007

FALCHOOK GS , Wolff RA, Varadhachary GR
Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

SCHMELER KM , Sun CC, Bodurka DC, T Deavers M, et al
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

GUIRGUIS A , Elishaev E, Oh SH, Tseng GC, et al
Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

DELOIA JA , Zamboni WC, Jones JM, Strychor S, et al
Expression and activity of taxane-metobolizing enzymes in ovarian tumors.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

GERSHENSON DM
Fallopian tube cancer: stepchild or mother?
Gynecol Oncol. 2007;107:386-7.
PubMed Text format Related articles

LAMBERT LA , Mansfield PF
Peritoneal dissemination of non-carcinoid primary appendiceal cancer.
Gynecol Oncol. 2007;107:592.
PubMed Text format Related articles

November 2007

MOORE RG , Brown AK, Miller MC, Skates S, et al
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

NUMNUM TM , Makhija S, Lu B, Wang M, et al
Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

EZAWA S , Suzuki N, Ohie S, Higashiguchi A, et al
A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: Potential new therapy for ovarian clear cell adenocarcinoma.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

TOMSOVA M , Melichar B, Sedlakova I, Steiner I, et al
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

VAN ALTENA AM , Wijnberg GJ, Kolwijck E, de Hullu JA, et al
A patient with bilateral immature ovarian teratoma presenting with paraneoplastic encephalitis.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

GERARDI MA , Santillan A, Meisner B, Zahurak ML, et al
A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

ZIVANOVIC O , Eisenhauer EL, Zhou Q, Iasonos A, et al
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

MOORE KN , Moxley KM, Fader AN, Axtell AE, et al
Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

October 2007

CHU S , Alexiadis M, Fuller PJ
Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

ERALP Y , Saip P, Aydin Z, Berkman S, et al
Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

SOUSSAN M , Wartski M, Cherel P, Fourme E, et al
Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

PENG B , Chang Q, Wang L, Hu Q, et al
Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

CHI DS , Palayekar MJ, Sonoda Y, Abu-Rustum NR, et al
Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

ALBERTS DS , Liu PY, Wilczynski SP, Clouser MC, et al
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest On
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

CICIN I , Saip P, Eralp Y, Selam M, et al
Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

PECTASIDES D , Xiros N, Papaxoinis G, Aravantinos G, et al
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

September 2007

KOLWIJCK E , Boss EA, van Altena AM, Beex LV, et al
Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: A case report and review of the literature.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

RUNZ S , Keller S, Rupp C, Stoeck A, et al
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

BRINTON LA , Sakoda LC, Frederiksen K, Sherman ME, et al
Relationships of uterine and ovarian tumors to pre-existing chronic conditions.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

August 2007

NAGAI Y , Inamine M, Hirakawa M, Kamiyama K, et al
Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.
Gynecol Oncol. 2007;.
PubMed Text format Related articles Abstract available

February 2007

JURETZKA MM , Barakat RR
Pelvic cytoreduction with rectosigmoid resection.
Gynecol Oncol. 2007;104.
PubMed Text format Related articles

CHI DS , Roberts CA, Abu-Rustum NR
Retroperitoneal lymph node dissection.
Gynecol Oncol. 2007;104.
PubMed Text format Related articles

EISENHAUER EL , Chi DS
Liver mobilization and diaphragm peritonectomy/resection.
Gynecol Oncol. 2007;104.
PubMed Text format Related articles

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.
Design: